Brian Daily, MD
Family Medicine · Wilmington, NCNPI 1427492503
Payments from drug & device makers
Across 78 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$230
- Pfizer$117
- Novo Nordisk$106
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$53
- AbbVie$53
- Amgen$45
- plus $555 from 20 others
What the payments were for
- Food & beverage$1,159100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $230 |
| Pfizer | 12 | $117 |
| Novo Nordisk | 7 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| AbbVie | 4 | $53 |
| Amgen(2 entities) | 3 | $45 |
| Lilly USA, LLC | 3 | $42 |
| Valeritas, Inc. | 3 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Merck | 3 | $36 |
| GSK | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Novartis | 2 | $28 |
| Genentech USA, Inc. | 2 | $28 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Ardelyx, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 2 | $16 |
| Organon | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$1,159 in reported general payments places this provider in the 70th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $22,222 |
| FarxigaDapagliflozin Propanediol | 16 | $16,367 |
| RybelsusSemaglutide | 11 | $10,233 |
| LinzessLinaclotide | 14 | $7,462 |
| TradjentaLinagliptin | 12 | $6,134 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $5,999 |
| Atorvastatin Calcium | 121 | $1,601 |
| Levothyroxine Sodium | 76 | $1,287 |
| Amlodipine Besylate | 87 | $797 |
| Lisinopril | 84 | $792 |
| Pantoprazole Sodium | 53 | $769 |
| Rosuvastatin Calcium | 67 | $695 |
| Tamsulosin Hcl | 60 | $691 |
| Metoprolol Succinate | 48 | $627 |
| Pravastatin Sodium | 35 | $618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $117 | $22,22222 claims |
| AstraZenecaFarxiga | $230 | $16,36716 claims |
| Novo NordiskRybelsus | $106 | $10,23311 claims |
| AbbVieLinzess | $53 | $7,46214 claims |
| Boehringer IngelheimTradjenta | $39 | $6,13412 claims |
| MerckJanumet Xr | $36 | $5,99911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Wilmington
- Barton WilliamsWilmington$17.3M
- William JonesWilmington$2.4M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.